SCHEMBL4283397

SCHEMBL4283397

O=C(Nc1n[nH]c2c1CN(S(=O)(=O)c1cccc(F)c1)C2)c1ccc(N2CCOCC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.63
ALK Q9UM73 1/20 0.55
ALDH1A1 P00352 3/20 0.51
NTRK1 P04629 3/20 0.50
NTRK3 Q16288 3/20 0.50
NTRK2 Q16620 3/20 0.50
CASP1 P29466 1/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50
AURKA O14965 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
CCNA2 P20248 2/20 0.49
CDK2 P24941 2/20 0.49
CCNA1 P78396 2/20 0.49
GAA P10253 1/20 0.49
KMT2A Q03164 1/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPT P10636 1/20 0.49
AURKB Q96GD4 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4291557 0.92 IGF1R (0.64) IGF1RALKNTRK1AURKACCNA2
SCHEMBL4287315 0.91 IGF1R (0.77) IGF1RALKNTRK1NTRK3NTRK2
SCHEMBL4287240 0.90 IGF1R (0.57) IGF1RALKALDH1A1NTRK1NTRK3
SCHEMBL4278087 0.89 IGF1R (0.62) IGF1RALKNTRK1NTRK3NTRK2
SCHEMBL4290171 0.89 IGF1R (0.64) IGF1RALKNTRK1NTRK3NTRK2
SCHEMBL4283625 0.86 IGF1R (0.62) IGF1RALKNTRK1NTRK3NTRK2
SCHEMBL4282329 0.86 IGF1R (0.56) IGF1RALKALDH1A1AURKACCNA2
SCHEMBL4283250 0.84 IGF1R (0.55) IGF1RALKALDH1A1AURKACCNA2
SCHEMBL4286487 0.84 IGF1R (0.55) IGF1RALKALDH1A1AURKACCNA2
SCHEMBL4287701 0.84 IGF1R (0.61) IGF1RALKNTRK1NTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP claimed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US claimed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS MAP3K19, CDK2, MAP3K1 IGF1R 530/4885ALK 443/4885ALDH1A1 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.